Current Expansions and Future Perspectives in Anticancer Drug Therapy

2021 ◽  
Vol 21 (11) ◽  
pp. 1336-1337
Author(s):  
Dinesh Kumar Mehta ◽  
Rina Das
Keyword(s):  
Drug Therapy ◽  
Anticancer Drug ◽  
Future Perspectives

Role of Pharmacogenomics in Antiepileptic Drug Therapy: Current Status and Future Perspectives

2018 ◽  
Vol 23 (37) ◽  
pp. 5760-5765 ◽  
Author(s):  
Antonio Gambardella ◽  
Angelo Labate ◽  
Laura Mumoli ◽  
Iscia Lopes-Cendes ◽  
Fernando Cendes
Keyword(s):  
Drug Therapy ◽  
Antiepileptic Drug ◽  
Current Status ◽  
Future Perspectives ◽  
Antiepileptic Drug Therapy

scholarly journals Bifunctional Aptamer Drug Carrier Enabling Selective and Efficient Incorporation of an Approved Anticancer Drug Irinotecan to Fibrin Gels

2020 ◽  
Vol 10 (23) ◽  
pp. 8755
Author(s):  
Hiroto Fujita ◽  
Yuka Kataoka ◽  
Masayasu Kuwahara
Keyword(s):  
Cell Proliferation ◽  
Drug Therapy ◽  
Anticancer Drug ◽  
Drug Carrier ◽  
Significant Inhibition ◽  
Tumor Cell Growth ◽  
Binding Properties ◽  
Fibrin Gels ◽  
Human Thrombin ◽  
Suppress Cell Proliferation

We have previously developed a bifunctional aptamer (bApt) binding to both human thrombin and camptothecin derivative (CPT1), and showed that bApt acts as a drug carrier under the phenomenon named selective oligonucleotide entrapment in fibrin polymers (SOEF), which enables efficient enrichment of CPT1 into fibrin gels, resulting in significant inhibition of tumor cell growth. However, although the derivative CPT1 exhibits anticancer activity, it is not an approved drug. In this study, we evaluated the binding properties of bApt to irinotecan, a camptothecin analog commonly used for anticancer drug therapy, in addition to unmodified camptothecin (CPT). Furthermore, we have revealed that irinotecan binds to bApt like CPT1 and is selectively concentrated on fibrin gels formed around the tumor cells under the SOEF phenomenon to suppress cell proliferation.

Lipid Nanomedicines for Anticancer Drug Therapy

2009 ◽  
Vol 5 (4) ◽  
pp. 323-343 ◽  
Author(s):  
Ander Estella-Hermoso de Mendoza ◽  
Miguel A. Campanero ◽  
Faustino Mollinedo ◽  
María J. Blanco-Prieto
Keyword(s):  
Drug Therapy ◽  
Anticancer Drug

scholarly journals Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

2011 ◽  
Vol 11 (3) ◽  
pp. 239-253 ◽  
Author(s):  
D. Chen ◽  
M. Frezza ◽  
S. Schmitt ◽  
J. Kanwar ◽  
Q. P. Dou
Keyword(s):  
Anticancer Drug ◽  
Proteasome Inhibitor ◽  
Current Status ◽  
Future Perspectives

scholarly journals Role of PET and PET/CT in Anticancer Drug Therapy Response Evaluation

2010 ◽  
Vol 1 (1) ◽  
pp. 91-97
Author(s):  
Rakesh Kumar ◽  
Varun Shandal ◽  
Suman Jana ◽  
Shamim A. Shamim ◽  
Arun Malhotra
Keyword(s):  
Drug Therapy ◽  
Anticancer Drug ◽  
Therapy Response ◽  
Response Evaluation ◽  
Pet Ct

scholarly journals Morphological Changes Induced by Anticancer Drug Therapy of Ovarian Cancer Cells in Ascitic Fluid

1981 ◽  
Vol 20 (2) ◽  
pp. 268-274
Author(s):  
Makoto YASUDA ◽  
Hiroaki INUI ◽  
Mitsui YOSHIOKA ◽  
Kazuhiko OCHIAI ◽  
Shogo TOKUDOME ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Therapy ◽  
Cancer Cells ◽  
Ascitic Fluid ◽  
Anticancer Drug ◽  
Morphological Changes ◽  
Ovarian Cancer Cells
Sign in / Sign up

Export Citation Format

Share Document